CORRECTION

Correction to: Olaratumab in Combination with Doxorubicin for the Treatment of Advanced Soft Tissue Sarcoma: An Evidence Review Group Perspective of a National Institute for Health and Clinical Excellence Single Technology Appraisal

Irina A. Tikhonova¹ · Tracey Jones-Hughes¹ · James Dunham¹ · Fiona C. Warren¹ · Sophie Robinson¹ · Peter Stephens² · Martin Hoyle¹

Published online: 24 February 2018
© Springer International Publishing AG, part of Springer Nature 2018

Correction to: PharmacoEconomics (2018) 36:39–49
<https://doi.org/10.1007/s40273-017-0568-3>

Page 41, Column 1, Section 3.1, paragraph 2, 1st sentence which

Previously read:

“In patients who had no prior lines of therapy for advanced disease, an investigator-assessed improvement in median progression-free survival (PFS) was 2.5 months (6.6 months, 95% confidence interval [CI] 4.1–8.3) in the OlaDox arm versus 4.1 months (95% CI 2.8–5.4) in the doxorubicin arm (hazard ratio [HR] 0.672; $p = 0.0615$) [8].”

Should read:

“In patients who had no prior lines of therapy for advanced disease, an investigator-assessed improvement in median progression-free survival (PFS) for OlaDox was 2.5 months [6.6 months (95% CI 3.1–9.3) in the OlaDox arm versus 4.1 months (95% CI 2.8–6.2) in the doxorubicin arm (hazard ratio [HR] = 0.771; $p = 0.2842$)] [7].”

The original article can be found online at <https://doi.org/10.1007/s40273-017-0568-3>.

✉ Irina A. Tikhonova
I.Tikhonova@exeter.ac.uk

¹ Peninsula Technology Assessment Group (PenTAG), Exeter, UK

² Royal Devon and Exeter NHS Foundation Trust, Exeter, UK